Study of Artificial Liver Support System Treatment for Liver Failure Caused by Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma

What this Trial Is About

Researchers are studying the use of an artificial liver support system ALSS to treat liver failure caused by immune checkpoint inhibitors in patients with hepatocellular carcinoma HCC. This condition arises in some patients receiving immune checkpoint inhibitors, a common treatment for advanced liver cancer, and can lead to severe liver failure requiring urgent treatment. The study aims to evaluate the safety and effectiveness of ALSS treatment to manage this serious liver complication. Participants are randomly assigned to one of two groups one group receives a combination of double plasma molecular adsorption system DPMAS and low volume plasma exchange LPE along with standard internal medical treatment, while the other group receives traditional plasma exchange PE with comprehensive internal medical treatment. Both treatments are given three times over two weeks, with specific volumes of plasma exchanged or adsorbed depending on the method used. During the 12-week study, researchers will monitor participants symptoms, laboratory test results, adverse events, and mortality rates. The main outcome measured is the mortality rate at 12 weeks, with additional assessment of liver function using the Model for End-Stage Liver Disease MELD score. This thorough follow-up includes regular clinical evaluations and laboratory tests to assess treatment impact and safety throughout the study period.

Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC